Cyclacel Financial Statements From 2010 to 2022

CYCC
 Stock
  

USD 0.84  0.05  5.62%   

Cyclacel Pharmaceuti financial statements provide useful quarterly and yearly information to potential Cyclacel Pharmaceuti investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cyclacel Pharmaceuti financial statements helps investors assess Cyclacel Pharmaceuti's valuation, profitability, and current liquidity needs.
Cyclacel Pharmaceuti does not presently have any fundamental signals for analysis.
.
  
Check Cyclacel Pharmaceuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclacel main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Cyclacel financial statements analysis is a perfect complement when working with Cyclacel Pharmaceuti Valuation or Volatility modules. It can also supplement Cyclacel Pharmaceuti's financial leverage analysis and stock options assessment as well as various Cyclacel Pharmaceuti Technical models . Continue to the analysis of Cyclacel Pharmaceuti Correlation against competitors.

Cyclacel Revenue Analysis

Cyclacel Pharmaceuti's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue 
 = 
Money Received 
Discounts and Returns 
More About Revenue | All Equity Analysis

Current Cyclacel Pharmaceuti Revenue

    
  150 K  
Most of Cyclacel Pharmaceuti's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyclacel Pharmaceuti is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Compare to competition

Based on the latest financial disclosure, Cyclacel Pharmaceuti reported 150 K of revenue. This is 100.0% lower than that of the Healthcare sector and 99.98% lower than that of the Biotechnology industry. The revenue for all United States stocks is 100.0% higher than that of the company.

Cyclacel Pharmaceuti Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cyclacel Pharmaceuti's current stock value. Our valuation model uses many indicators to compare Cyclacel Pharmaceuti value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyclacel Pharmaceuti competition to find correlations between indicators driving Cyclacel Pharmaceuti's intrinsic value. More Info.
Cyclacel Pharmaceuti is rated second in z score category among related companies. It is number one stock in price to sales category among related companies fabricating about  3.16  of Price to Sales per Z Score. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cyclacel Pharmaceuti by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cyclacel Pharmaceuti's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclacel Pharmaceuti's earnings, one of the primary drivers of an investment's value.

About Cyclacel Pharmaceuti Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cyclacel Pharmaceuti income statement, its balance sheet, and the statement of cash flows. Cyclacel Pharmaceuti investors use historical funamental indicators, such as Cyclacel Pharmaceuti's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cyclacel Pharmaceuti investors may use each financial statement separately, they are all related. The changes in Cyclacel Pharmaceuti's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cyclacel Pharmaceuti's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cyclacel Pharmaceuti Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cyclacel Pharmaceuti. Please read more on our technical analysis and fundamental analysis pages.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cyclacel Pharmaceuti without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Manager Now

   

Portfolio Manager

State of the art Portfolio Manager to monitor and improve performance of your invested capital
All  Next Launch Module

Pair Trading with Cyclacel Pharmaceuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuti will appreciate offsetting losses from the drop in the long position's value.

Moving against Cyclacel Pharmaceuti

-0.63SBUXStarbucks Corp TrendingPairCorr
-0.62TWTRTwitter DelistingPairCorr
-0.53MRNAModerna Potential GrowthPairCorr
-0.52SGMLSigma Lithium Corp Buyout TrendPairCorr
The ability to find closely correlated positions to Cyclacel Pharmaceuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuti to buy it.
The correlation of Cyclacel Pharmaceuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Cyclacel Pharmaceuti Correlation against competitors. Note that the Cyclacel Pharmaceuti information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuti price analysis, check to measure Cyclacel Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuti is operating at the current time. Most of Cyclacel Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cyclacel Pharmaceuti's price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuti to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Is Cyclacel Pharmaceuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuti. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
11.2 M
Return On Assets
(0.42) 
Return On Equity
(0.60) 
The market value of Cyclacel Pharmaceuti is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuti's value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuti's market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Cyclacel Pharmaceuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.